KR920000322A - 세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도 - Google Patents

세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도 Download PDF

Info

Publication number
KR920000322A
KR920000322A KR1019910010126A KR910010126A KR920000322A KR 920000322 A KR920000322 A KR 920000322A KR 1019910010126 A KR1019910010126 A KR 1019910010126A KR 910010126 A KR910010126 A KR 910010126A KR 920000322 A KR920000322 A KR 920000322A
Authority
KR
South Korea
Prior art keywords
xanthine
derivative
pharmaceutical combination
cephalosporin
oxohexyl
Prior art date
Application number
KR1019910010126A
Other languages
English (en)
Other versions
KR100205161B1 (ko
Inventor
클레셀 노베르트
림버트 미카엘
슈린너 엘마
Original Assignee
아이젠브루크, 라피체
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이젠브루크, 라피체, 훽스트 아크티엔게젤샤프트 filed Critical 아이젠브루크, 라피체
Publication of KR920000322A publication Critical patent/KR920000322A/ko
Application granted granted Critical
Publication of KR100205161B1 publication Critical patent/KR100205161B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 세팔로스포린 유도체 하나 이상 및 크산틴 유도체 하나 이상을 함유하는 약제학적 복합제.
  2. 제1항에 있어서, 세팔로스포린 유도체가 세포탁심, 세포디짐, 세프트리악손, 세프메녹심 또는 세프피롬인 약제학적 복합제.
  3. 제1항 또는 제2항에 있어서, 세팔로스포린 유도체가 세포탁심인 약제학적 복합제.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 크산틴 유도체가 1－헥실－3, 7－디메틸크산틴, 1－(5－하이드록시헥실)－3, 7－디메틸크산틴, 3, 7－디메틸－1－(5－옥소헥실)－크산틴, 7－(5－하디드록시헥실)－1, 3－디메틸크산틴, 1,3－디메틸－7－(5－옥소헥실)－크산틴, 1, 3－디－n－부틸－7－(2－옥소프로필)－크산틴, 1, 3－디－n－부틸－7－(3－옥소부틸)－크산틴, 1－(5－하이드록시헥실)－3－메틸－7－프로필크산틴 및 3－메틸－1－(5－옥소헥실)－7－프로필크산틴(프로펜토필린), 3－7－디메틸－1－(5－옥소헥실)－크산틴 (펜톡시필린), 7－프로프릴, 또는 7－에톡시메틸－1－(5－하이드록시－5－메틸헥실)－3－메틸크산틴 또는 1－(5－하이드록시－5－메틸헥실)－3－메틸크산틴인 약제학적 복합제.
  5. 제1항 내지 제4항중 어느 한항에 있어서, 크산틴 유도체가 1－(5－하이드록시－5－메틸헥실)－3－메틸크산틴인 약제학적 복합제.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, 세포 탁심 및 1－(5－하이드록시－5－메틸헥실)－3－메틸크산틴을 함유하는 약제학적 복합제.
  7. 약제를 제조하기 위한, 세팔로스포린 유도체 하나 이상 및 크산틴 유도체 하나 이상의 용도.
  8. 세팔로스포린 유도체 하나 이상 및 크산틴 유도체 하나 이상을, 경우에 따라, 적합한 보조제 및/또는 부형제와 함께 사용하여 적합한 투여형태로 하여, 제1항 내지 제6항중 어느 한 항에서 청구한 약제학적 복합제를 제조하는 방법.
  9. 세균 감염성 질환을 예방하거나 치료하기 위한, 세팔로스포린 유도체 하나 이상 및 크산틴 하나 이상의 용도.
  10. 패혈증 쇼크를 예방하거나 치료하기 위한, 세팔로스포린 유도체 하나 이상 및 크산틴 유도체 하나 이상의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910010126A 1990-06-20 1991-06-19 세팔로스포린 유도체와 크산틴 유도체를 함유하는, 세균 감염성 질환 예방 및 치료용 약제학적 복합 제제 KR100205161B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4019571A DE4019571A1 (de) 1990-06-20 1990-06-20 Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
DEP4019571.6 1990-06-20

Publications (2)

Publication Number Publication Date
KR920000322A true KR920000322A (ko) 1992-01-29
KR100205161B1 KR100205161B1 (ko) 1999-07-01

Family

ID=6408686

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910010126A KR100205161B1 (ko) 1990-06-20 1991-06-19 세팔로스포린 유도체와 크산틴 유도체를 함유하는, 세균 감염성 질환 예방 및 치료용 약제학적 복합 제제

Country Status (26)

Country Link
US (1) US5350753A (ko)
EP (1) EP0462506B1 (ko)
JP (1) JP3213339B2 (ko)
KR (1) KR100205161B1 (ko)
CN (1) CN1057390A (ko)
AT (1) ATE144901T1 (ko)
AU (1) AU643291B2 (ko)
BR (1) BR9102554A (ko)
CA (1) CA2044977A1 (ko)
CZ (1) CZ282285B6 (ko)
DE (2) DE4019571A1 (ko)
DK (1) DK0462506T3 (ko)
ES (1) ES2093656T3 (ko)
FI (1) FI912968A (ko)
GR (1) GR3021568T3 (ko)
HR (1) HRP940708B1 (ko)
HU (1) HU212937B (ko)
IE (1) IE76290B1 (ko)
IL (1) IL98535A (ko)
MX (1) MX26309A (ko)
NO (1) NO912382L (ko)
NZ (1) NZ238580A (ko)
PT (1) PT98028B (ko)
RU (1) RU2095063C1 (ko)
YU (1) YU48415B (ko)
ZA (1) ZA914709B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177075A3 (ko) * 2011-06-23 2013-03-28 주식회사 아리메드 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1090795A (en) 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
PT812844E (pt) 1996-06-07 2003-03-31 Hoechst Ag Utilizacao de derivados de teofilina para o tratamento e profilaxia de estados de choque novos compostos de xantina e processo para a sua preparacao
JP2006510357A (ja) * 2002-11-22 2006-03-30 ザ ジョーンズ ホプキンズ ユニバーシティ 認識障害の処置のための標的

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177075A3 (ko) * 2011-06-23 2013-03-28 주식회사 아리메드 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
KR101315483B1 (ko) * 2011-06-23 2013-10-07 주식회사 아리바이오 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물

Also Published As

Publication number Publication date
DE59108321D1 (de) 1996-12-12
CS187891A3 (en) 1992-02-19
DE4019571A1 (de) 1992-01-02
CZ282285B6 (cs) 1997-06-11
JP3213339B2 (ja) 2001-10-02
HRP940708B1 (en) 1998-12-31
PT98028A (pt) 1992-03-31
HU912048D0 (en) 1991-12-30
BR9102554A (pt) 1992-01-21
FI912968A (fi) 1991-12-21
CA2044977A1 (en) 1991-12-21
IL98535A0 (en) 1992-07-15
KR100205161B1 (ko) 1999-07-01
US5350753A (en) 1994-09-27
EP0462506B1 (de) 1996-11-06
HU212937B (en) 1996-12-30
HUT57986A (en) 1992-01-28
FI912968A0 (fi) 1991-06-18
YU48415B (sh) 1998-07-10
EP0462506A1 (de) 1991-12-27
IE76290B1 (en) 1997-10-08
NZ238580A (en) 1993-10-26
ZA914709B (en) 1992-03-25
AU7848291A (en) 1992-01-02
IE912107A1 (en) 1992-01-01
DK0462506T3 (da) 1996-11-25
NO912382L (no) 1991-12-23
ES2093656T3 (es) 1997-01-01
HRP940708A2 (en) 1997-02-28
GR3021568T3 (en) 1997-02-28
PT98028B (pt) 1998-11-30
CN1057390A (zh) 1992-01-01
JPH04230219A (ja) 1992-08-19
RU2095063C1 (ru) 1997-11-10
YU108291A (sh) 1995-03-27
NO912382D0 (no) 1991-06-19
ATE144901T1 (de) 1996-11-15
IL98535A (en) 1996-01-19
MX26309A (es) 1994-02-28
AU643291B2 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
AU2276100A (en) Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
SE7509675L (sv) Forfarande for framstellning av purinforeningar och salter derav
LU91370I2 (fr) Nelarbine, ou un dérivé physiologiquement acceptable (atriance)
RS52836B (en) HYDROCHLORIDES AND HYDRATES 1 - [(3-CYANOPYRIDIN-2-yl) METHYL] -3-METHYL-7- (2-BUTIN-1-yl) -8- (3-AMINOPIPERIDIN-1-yl) XANTINE, THEIR PREPARATION AND THEIR APPLICATION AS A MEDICINE
KR920000322A (ko) 세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도
FI20000976A (fi) Tuotteita
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
AU631679B2 (en) Use of a derivative of 1,3,7-trimethylxanthine for the treatment of memory disorders, intellectual disorders of ageing and alzheimer's disease
WO1999012545A3 (en) Medicaments containing acyclovir
EP0351215A3 (en) Ester of 9-(2-hydroxyethoxymethyl) guanine
MX9704502A (es) Tratamiento de enfermedad autoinmune usando derivados de 2-amino purina.
SE7702231L (sv) Sett att framstella en substituerad purin
AR005551A1 (es) Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
FI945446A0 (fi) Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi
MX9400215A (es) Compuestos farmaceuticos.
ES2037672T3 (es) Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
Rosen et al. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations
NO951887L (no) Xantin-derivater som diuretiske midler
Reddy Toronto Baptist Seminary & Bible College
REESE et al. The use of aminophylline in neuropsychiatric disorders associated with cerebral arteriosclerosis and hypertensive encephalopathy
Granbery The Demoniac and the Returning Demon. An Exposition of Matt. 12: 43-45; Luke 11: 23-26
FR2027273A1 (en) Methyl xanthines having cardiac activityh
Bjornson et al. Patterns of use: Topical and oral acyclovir.
SE8702227D0 (sv) New use
KR890001560A (ko) 항바이어러스 조성물

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee